Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 801–900 of 1,021
Biallelic DICER1 Mutations in Sporadic Pleuropulmonary Blastoma
Seki, M., Yoshida, K., Shiraishi, Y., Shimamura, T., Sato, Y., Nishimura, R., Okuno, Y., Chiba, K., Tanaka, H., Kato, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2470 · Cited by 88
Functional polymorphisms in Nrf2: implications for human disease
Cho, H., Marzec, J. M., & Kleeberger, S. R. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.012 · Cited by 97
The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2
Xu, X., Huang, L., Futtner, C., Schwab, B., Rampersad, R. R., Lu, Y., Sporn, T. A., Hogan, B. L. M., & Onaitis, M. W. (2014) · Genes & Development · doi:10.1101/gad.243717.114 · Cited by 82
PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting
Ciuffreda, L., Falcone, I., Incani, U. C., Curatolo, A. D., Conciatori, F., Matteoni, S., Vari, S., Vaccaro, V., Cognetti, F., & Milella, M. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.07.002 · Cited by 90
Integrated RNA and DNA sequencing improves mutation detection in low purity tumors
Wilkerson, M. D., Cabanski, C. R., Sun, W., Hoadley, K. A., Walter, V., Mose, L. E., Troester, M. A., Hammerman, P. S., Parker, J. S., Perou, C. M., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku489 · Cited by 87
Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer
Bennett, C. W., Berchem, G., Kim, Y. J., & El‐Khoury, V. (2016) · Oncotarget · doi:10.18632/oncotarget.11717 · Cited by 92
Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.005 · Cited by 88
Gacesa, R., Lawrence, K. P., Georgakopoulos, N. D., Yabe, K., Dunlap, W. C., Barlow, D. J., Wells, G., Young, A. R., & Long, P. F. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.020 · Cited by 82
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research
Ooi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.016 · Cited by 90
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator
Li, F., Qasim, S., Li, D., & Dou, Q. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.018 · Cited by 97
Fukusumi, T., Guo, T. W., Sakai, A., Ando, M., Ren, S., Haft, S. J., Liu, C., Amornphimoltham, P., Gutkind, J. S., & Califano, J. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1366 · Cited by 94
Targeted therapies in development for non-small cell lung cancer
Dy, G. K., & Reungwetwattana, T. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.123972 · Cited by 90
Ramalingam, S. S., Blais, N., Mazieres, J., Reck, M., Jones, C. M., Juhasz, E., Urban, L., Orlov, S., Barlesi, F., Kio, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3069 · Cited by 81
Ma, Y., & Li, M. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-01856-4 · Cited by 84
Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell Carcinomas (HNSCC)
Pérez‐Sayáns, M., Chamorro-Petronacci, C. M., Lorenzo‐Pouso, A. I., Padín-Iruegas, E., Carrión, A. B., Peñaranda, J. M. S., & Garcı́a, A. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111896 · Cited by 80
Artificial intelligence and big data facilitated targeted drug discovery
Liu, B., He, H., Luo, H., Zhang, T., & Jiang, J. (2019) · Stroke and Vascular Neurology · doi:10.1136/svn-2019-000290 · Cited by 81
Tumor diversity and the trade-off between universal cancer tasks
Hausser, J., Székely, P., Bar, N., Zimmer, A., Sheftel, H., Caldas, C., & Alon, U. (2019) · Nature Communications · doi:10.1038/s41467-019-13195-1 · Cited by 88
Salehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 94
Takahashi, S., Asada, K., Takasawa, K., Shimoyama, R., Sakai, A., Bolatkan, A., Shinkai, N., Kobayashi, K., Komatsu, M., Kaneko, S., et al. (2020) · Biomolecules · doi:10.3390/biom10101460 · Cited by 81
Clinical application of a lung cancer organoid (tumoroid) culture system
Yokota, E., Iwai, M., Yukawa, T., Yoshida, M., Naomoto, Y., Haisa, M., Monobe, Y., Takigawa, N., Guo, M., Maeda, Y., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00166-3 · Cited by 91
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
Seegobin, K., Majeed, U., Wiest, N. E., Manochakian, R., Lou, Y., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750657 · Cited by 89
Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma
Riester, M., Werner, L. L., Joaquim Bellmunt, B., Selvarajah, S., Guancial, E. A., Weir, B. A., Stack, E. C., Park, R. S., O'Brien, R., Schutz, F. A. B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0759 · Cited by 97
Validation of a blood protein signature for non-small cell lung cancer
Mehan, M. R., Williams, S. A., Siegfried, J. M., Bigbee, W. L., Weissfeld, J. L., Wilson, D. O., Pass, H. I., Rom, W. N., Muley, T., Meister, M. A., et al. (2014) · Clinical Proteomics · doi:10.1186/1559-0275-11-32 · Cited by 86
Nakagaki, T., Tamura, M., Kobashi, K., Koyama, R., Fukushima, H., Ohashi, T., Idogawa, M., Ogi, K., Hiratsuka, H., Tokino, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19262 · Cited by 91
Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
Čihorić, N., Savić, S., Schneider, S. S., Ackermann, I., Bichsel-Naef, M., Schmid, R. A., Lardinois, D., Gugger, M., Bubendorf, L., Zlobec, I., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.229 · Cited by 82
Ilié, M., Nunes, M., Blot, L., Hofman, V., Long-Mira, É., Butori, C., Selva, É., Merino‐Trigo, A., Vénissac, N., Mouroux, J., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.357 · Cited by 80
Khunger, A., Khunger, M., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618767611 · Cited by 89
Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC
Hellyer, J. A., Padda, S. K., Diehn, M., & Wakelee, H. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.015 · Cited by 93
Zhou, S., Huang, Y., Liu, H., Zhou, X., Yuan, M., Hou, F., Wang, L., & Jiang, W. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.12.018 · Cited by 81
Cell-type heterogeneity: Why we should adjust for it in epigenome and biomarker studies
Qi, L., & Teschendorff, A. E. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01253-3 · Cited by 100
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
Andrini, E., Marchese, P. V., de Biase, D., Mosconi, C., SIEPE, G., Panzuto, F., Ardizzoni, A., Campana, D., & Lamberti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051461 · Cited by 89
Ren, J.-G., Seth, P., Clish, C. B., Lorkiewicz, P., Higashi, R. M., Lane, A. N., Fan, T. W. ‐., & Sukhatme, V. P. (2014) · Scientific Reports · doi:10.1038/srep05414 · Cited by 92
Brown, K. C., Perry, H. E., Lau, J. K., Jones, D. V., Pulliam, J. F., Thornhill, B. A., Crabtree, C. M., Luo, H., Chen, Y., & Dasgupta, P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.501601 · Cited by 87
A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data
Li, B., & Li, J. Z. (2014) · Genome Biology · doi:10.1186/preaccept-5267400171382091 · Cited by 80
Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors
Asiedu, M. K., Thomas, C. F., Dong, J., Schulte, S. C., Khadka, P., Sun, Z., Kosari, F., Jen, J., Molina, J. R., Vasmatzis, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0252 · Cited by 85
The combinatorial complexity of cancer precision medicine
Klauschen, F., Andreeff, M., Keilholz, U., Dietel, M., & Stenzinger, A. (2014) · Oncoscience · doi:10.18632/oncoscience.66 · Cited by 80
Middleton, G., Crack, L. R., Popat, S., Swanton, C., Hollingsworth, S. J., Buller, R., Walker, I., Carr, T. H., Wherton, D., & Billingham, L. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv394 · Cited by 82
Thangavelu, P. U., Krenács, T., Dray, E. V., & Duijf, P. H. G. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0290-6 · Cited by 85
Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma
Toyokawa, G., Kozuma, Y., Matsubara, T., Haratake, N., Takamori, S., Akamine, T., Takada, K., Katsura, M., Shimokawa, M., Shoji, F., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.108 · Cited by 79
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers
Tanaka, H., & Watanabe, T. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.019 · Cited by 84
Adib, E., Nassar, A. H., Alaiwi, S. A., Groha, S., Akl, E. W., Sholl, L. M., Michael, K., Awad, M. M., Janne, P. A., Gusev, A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01041-x · Cited by 91
Ebisudani, T., Hamamoto, J., Togasaki, K., Mitsuishi, A., Sugihara, K., Shinozaki, T., Fukushima, T., Kawasaki, K., Seino, T., Oda, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112212 · Cited by 85
Jeon, M. J., Chun, S., Kim, D., Kwon, H., Jang, E. K., Kim, T. Y., Kim, W. B., Shong, Y. K., Jang, S. J., Song, D. E., et al. (2016) · Thyroid · doi:10.1089/thy.2015.0506 · Cited by 79
Wang, G. X., Tu, H.-C., Dong, Y., Skanderup, A. J., Wang, Y., Takeda, S., Ganesan, Y. T., Han, S. I., Liu, H., Hsieh, J. J.-D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.030 · Cited by 80
Sun, Q., Li, S., Wang, Y., Peng, H., Zhang, X., Zheng, Y., Li, C., Li, L., Chen, R., Chen, X., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-017-0034-y · Cited by 87
Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 87
Parker, A. L., Bowman, E. D., Zingone, A., Ryan, B. M., Cooper, W. A., Kohonen‐Corish, M. R. J., Harris, C. C., & Cox, T. R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01127-6 · Cited by 81
FGFR families: biological functions and therapeutic interventions in tumors
Liu, Q., Huang, J., Yan, W., Liu, Z., Liu, S., & Fang, W. (2023) · MedComm · doi:10.1002/mco2.367 · Cited by 91
Beyond antioxidant genes in the ancient Nrf2 regulatory network
Lacher, S. E., Lee, J. S., Wang, X., Campbell, M. R., Bell, D. A., & Slattery, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.044 · Cited by 77
Schwaederle, M. C., Elkin, S. K., Tomson, B. N., Carter, J. L., & Kurzrock, R. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1053669 · Cited by 86
The Mcm2-7 Replicative Helicase: A Promising Chemotherapeutic Target
Simon, N. W., & Schwacha, A. (2014) · BioMed Research International · doi:10.1155/2014/549719 · Cited by 83
Wang, E., Zou, J., Zaman, N., Beitel, L. K., Trifiro, M., & Paliouras, M. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.002 · Cited by 77
Cancer Stem Cell Division: When the Rules of Asymmetry Are Broken
Mukherjee, S., Kong, J., & Brat, D. J. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0442 · Cited by 84
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
Graham, N. A., Minasyan, A., Lomova, A., Cass, A. A., Balanis, N. G., Friedman, M., Chan, S. T., Zhao, S. R., Delgado, A., Go, J. L., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167159 · Cited by 100
Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies
Munnik, C., Xaba, M. P., Malindisa, S. T., Russell, B. L., & Sooklal, S. A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.949241 · Cited by 87
Chen, M., Lu, H., Copley, S. J., Han, Y., Logan, A., Viola, P., Cortellini, A., Pinato, D. J., Power, D., & Aboagye, E. O. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.089 · Cited by 82
Activating ERBB4 mutations in non-small cell lung cancer
Kurppa, K. J., Denessiouk, K. A., Johnson, M. S., & Elenius, K. (2015) · Oncogene · doi:10.1038/onc.2015.185 · Cited by 90
Li, Y., Xuan, J., Song, Y., Qi, W., He, B., Wang, P., & Qin, L. (2015) · ACS Nano · doi:10.1021/acsnano.5b07357 · Cited by 77
Identification of ZDHHC14 as a novel human tumour suppressor gene
Yeste‐Velasco, M., Mao, X., Grose, R. P., Kudahetti, S. C., Lin, D., Marzec, J., Vasiljević, N., Chaplin, T., Xue, L., Xu, M., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4327 · Cited by 77
Shoja, Y., Kermanpur, A., & Karimzadeh, F. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.04.013 · Cited by 76
Edelman, M. J., Redman, M. W., Albain, K. S., McGary, E. C., Rafique, N. M., Petro, D. P., Waqar, S. N., Minichiello, K., Miao, J., Papadimitrakopoulou, V. A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.027 · Cited by 87
Xue, Y., Morris, J. L., Yang, K., Fu, Z., Zhu, X., Johnson, F. D., Meehan, B., Witkowski, L., Yasmeen, A., Golenár, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25260-9 · Cited by 91
Cutaneous Squamous Cell Carcinoma: An Updated Review
Jiang, R., Fritz, M., & Que, S. K. T. (2024) · Cancers · doi:10.3390/cancers16101800 · Cited by 91
RNA sequencing identifies novel markers of non-small cell lung cancer
Han, S., Kim, W. J., Hong, Y., Hong, S., Lee, S., Ryu, D. R., Lee, W.-H., Cho, Y. H., Lee, S., Ryu, Y.-J., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.018 · Cited by 82
Lozano, M. D., Echeveste, J. I., Abengozar‐Muela, M., Mejías, L. D., Idoate, M. A., Calvo, A., & de Andrea, C. E. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0208-ra · Cited by 82
Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer
Faraji, F., Zaidi, M. A., Fakhry, C., & Gaykalova, D. A. (2017) · Microbes and Infection · doi:10.1016/j.micinf.2017.06.001 · Cited by 98
Rodon, J. A., Soria, J., Berger, R., Batist, G., Tsimberidou, A. M., Bresson, C., Lee, J. J., Rubin, E., Onn, A., Schilsky, R. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv191 · Cited by 80
The Regulation of NRF2 by Nutrient-Responsive Signaling and Its Role in Anabolic Cancer Metabolism
Lee, S. B., Sellers, B. N., & DeNicola, G. M. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7356 · Cited by 80
Lazarus, K., Hadi, F., Zambon, E., Bach, K., Santolla, M., Watson, J., Correia, L., Das, M., Ugur, R., Pensa, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05790-5 · Cited by 65
Liang, Q., Ma, D., Zhu, X., Wang, Z., Sun, T., Shen, C., Yan, T., Tian, X., Yu, T., Guo, F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2133 · Cited by 78
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1
Romero, R., Sánchez-Rivera, F. J., Westcott, P. M. K., Mercer, K. L., Bhutkar, A., Muir, A., González Robles, T. J., Lamboy Rodríguez, S., Liao, L. Z., Ng, S. R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0071-1 · Cited by 75
A Clinician’s Guide to Bioinformatics for Next-Generation Sequencing
Larson, N. B., Oberg, A. L., Adjei, A. A., & Wang, L. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.006 · Cited by 100
Wang, Y., Pascoe, H. G., Brautigam, C. A., He, H., & Zhang, X. (2013) · eLife · doi:10.7554/elife.01279 · Cited by 80
Biology of MET: a double life between normal tissue repair and tumor progression.
Petrini, I. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.03.58 · Cited by 75
Lee, W.-C., Diao, L., Wang, J., Zhang, J., Roarty, E. B., Varghese, S., Chow, C.-W. B., Fujimoto, J., Behrens, C., Cascone, T., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0029-3 · Cited by 80
Monitoring of Technical Variation in Quantitative High-Throughput Datasets
Lauss, M., Visne, I., Kriegner, A., Ringnér, M., Jönsson, G., & Höglund, M. (2013) · Cancer Informatics · doi:10.4137/cin.s12862 · Cited by 74
Rühm, W., Eidemüller, M., & Kaiser, J. C. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1310405 · Cited by 77
Qiu, Z., bi, J. F., Gazdar, A. F., & Song, K. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22460 · Cited by 76
Xiao, J., Lu, X., Chen, X., Zou, Y., Liu, A., Li, W., He, B., He, S., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17606 · Cited by 75
FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
Yuan, H., Li, Z., Shao, J., Ji, W., Xia, W., & Lu, S. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0534-0 · Cited by 77
Shi, Y.-X., Wáng, Y., Li, X., Zhang, W., Zhou, H., Yin, J., & Liu, Z. (2017) · BMC Genomics · doi:10.1186/s12864-017-4223-3 · Cited by 74
Cetuximab for treating non-small cell lung cancer
Mazzarella, L., Guida, A., & Curigliano, G. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1452906 · Cited by 86
Chae, Y. K., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Agte, S., Giles, F. J., & Chuang, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39594-4 · Cited by 79
Hai, J., Zhang, H., Zhou, J. R., Wu, Z., Chen, T., Papadopoulos, E., Dowling, C. M., Pyon, V., Pan, Y., Liu, J. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1627 · Cited by 77
Patel, A. S., Yoo, S., Kong, R., Sato, T., Sinha, A., Karam, S., Bao, L., Fridrikh, M., Emoto, K., Nudelman, G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc2578 · Cited by 79
KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub
Scalera, S., Mazzotta, M., Cortile, C., Krasniqi, E., Maria, R. D., Cappuzzo, F., Ciliberto, G., & Maugeri‐Saccà, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.011 · Cited by 83
Dysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 80
DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies
Hua, X., Xu, H., Yang, Y., Zhu, J., Liu, P., & Lü, Y. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.07.003 · Cited by 82
Li, X., Zhang, Y., Zhao, L., Wang, L., Wu, Z., Mei, Q., Nie, J., Li, X., Li, Y., Fu, X., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu330 · Cited by 74
Identifying Cancer Subtypes from miRNA-TF-mRNA Regulatory Networks and Expression Data
Xu, T., Le, T. D., Liu, L., Wang, R., Sun, B., & Li, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152792 · Cited by 81
Hou, S., Zhou, S., Qin, Z., Liu, Y., Han, X., Yao, S., & Ji, H. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.009 · Cited by 81
Tyler, M. P. H., & Tirosh, I. (2021) · Nature Communications · doi:10.1038/s41467-021-22800-1 · Cited by 80
Gao, Z., Hong, B., Li, Y., Zhang, X., Wu, J., Wang, C., Zhang, X., Gong, T., Zheng, Y., Meng, D., et al. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102652 · Cited by 78
Node-aligned Graph Convolutional Network for Whole-slide Image Representation and Classification
Guan, Y., Zhang, J., Tian, K., Yang, S., Dong, P., Xiang, J., Yang, W., Huang, J., Zhang, Y., & Han, X. (2022) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr52688.2022.01825 · Cited by 100
Gou, L.-Y., Niu, F., Wu, Y.-L. L. C., & Zhong, W. (2015) · Cancer · doi:10.1002/cncr.29531 · Cited by 74
Bria, E., Pilotto, S., Amato, E., Fassan, M., Novello, S., Peretti, U., Vavalà, T., Kinspergher, S., Righi, L., Santo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3727 · Cited by 73
Biobanking for Personalized Medicine
Liu, A., & Pollard, K. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-20579-3_5 · Cited by 78
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
Dunnett-Kane, V., Burkitt-Wright, E., Blackhall, F. H., Malliri, A., Evans, D. G., & Lindsay, C. R. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.291 · Cited by 66
ALK-rearrangements and testing methods in non-small cell lung cancer: a review
Shackelford, R. E., Vora, M., Mayhall, K., & Cotelingam, J. D. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.3 · Cited by 83
Koppula, P., Olszewski, K. L., Zhang, Y., Kondiparthi, L., Liu, X., Lei, G., Das, M., Fang, B., Poyurovsky, M. V., & Gan, B. (2021) · iScience · doi:10.1016/j.isci.2021.102649 · Cited by 82
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.